SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark.

On June 24, 2026, after the market closed, ARS published a press release announcing that no new commercial formulary additions or coverage decisions had been issued for neffy in the July 1, 2026 cycle, and that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027.

On this news, ARS's stock price fell $2.52, or 23.9%, to close at $8.02 per share on June 25, 2026, on unusually heavy trading volume.

A securities class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased the company's securities during the Class Period.

The complaint alleges that defendants made overwhelmingly positive statements to investors while simultaneously disseminating false and misleading statements and/or concealing material adverse facts regarding the expected timeline for expanded insurance coverage of neffy through CVS Caremark.

Specifically, the lawsuit alleges that defendants failed to disclose that no new commercial formulary additions or coverage decisions would be issued for neffy in the July 1, 2026 cycle, and that CVS Caremark had allegedly reserved its coverage decision until January 2027.

When this information was disclosed on June 24, 2026, after market close, ARS's stock price allegedly fell $2.52, or approximately 23.9%, to close at $8.02 per share on June 25, 2026, on unusually h...